What are the effects of varenicline compared with nicotine replacement therapy on long-term smoking cessation and clinically important outcomes? Protocol for a prospective cohort study

被引:10
|
作者
Davies, Neil M. [1 ,2 ]
Taylor, Gemma [1 ,2 ]
Taylor, Amy E. [1 ,3 ]
Thomas, Kyla H. [2 ]
Windmeijer, Frank [1 ,4 ]
Martin, Richard M. [1 ,2 ]
Munafo, Marcus R. [1 ,3 ]
机构
[1] Univ Bristol, MRC, Integrat Epidemiol Unit, Bristol, Avon, England
[2] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England
[3] Univ Bristol, Sch Expt Psychol, Bristol, Avon, England
[4] Univ Bristol, Dept Econ, Bristol, Avon, England
来源
BMJ OPEN | 2015年 / 5卷 / 11期
基金
美国国家卫生研究院; 英国医学研究理事会;
关键词
SELF-HARM; RISK; VALIDATION; HEALTH; IDENTIFICATION; PRESCRIPTIONS; DEPRESSION; VALIDITY; DATABASE; SUICIDE;
D O I
10.1136/bmjopen-2015-009665
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Smoking is a major avoidable cause of ill-health and premature death. Treatments that help patients successfully quit smoking have an important effect on health and life expectancy. Varenicline is a medication that can help smokers successfully quit smoking. However, there are concerns that it may cause adverse effects, such as increase in the occurrence of depression, self-harm and suicide and cardiovascular disease. In this study we aim to examine the effects of varenicline versus other smoking cessation pharmacotherapies on smoking cessation, health service use, all-cause and cause-specific mortality and physical and mental health conditions. Methods: In this project we will investigate the effects of varenicline compared to nicotine replacement therapies on: (1) long-term smoking cessation and whether these effects differ by area level deprivation; and (2) the following clinically-important outcomes: rate of general practice and hospital attendance; all-cause mortality and death due to diseases of the respiratory system and cardiovascular disease; and a primary care diagnosis of respiratory illness, myocardial infarction or depression and anxiety. The study is based on a cohort of patients prescribed these smoking cessation medications from the Clinical Practice Research Datalink (CPRD). We will use three methods to overcome confounding: multivariable adjusted Cox regression, propensity score matched Cox regression, and instrumental variable regression. The total expected sample size for analysis will be at least 180 000. Follow-up will end with the earliest of either an 'event' or censoring due to the end of registration or death. Ethics and dissemination: Ethics approval was not required for this study. This project has been approved by the CPRD's Independent Scientific Advisory Committee (ISAC). We will disseminate our findings via publications in international peer-reviewed journals and presentations at international conferences.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective cohort study of electronic medical records
    Taylor, Gemma M. J.
    Taylor, Amy E.
    Thomas, Kyla H.
    Jones, Timothy
    Martin, Richard M.
    Munafo, Marcus R.
    Windmeijer, Frank
    Davies, Neil M.
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2017, 46 (06) : 1948 - 1957
  • [2] Effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective, cohort study of electronic medical records
    Taylor, Gemma M. J.
    Taylor, Amy E.
    Thomas, Kyla H.
    Jones, Tim
    Martin, Richard M.
    Munafo, Marcus R.
    Windmeijer, Frank
    Davies, Neil M.
    [J]. LANCET, 2016, 388 : 107 - 107
  • [3] Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the “real world”
    Daniel Kotz
    Jamie Brown
    Robert West
    [J]. BMC Public Health, 14
  • [4] Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the "real world"
    Kotz, Daniel
    Brown, Jamie
    West, Robert
    [J]. BMC PUBLIC HEALTH, 2014, 14
  • [5] Which is the best primary medication for long-term smoking cessation - nicotine replacement therapy, bupropion or varenicline?
    Doggrell, Sheila A.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (17) : 2903 - 2915
  • [6] Long-term effectiveness and safety of varenicline and nicotine replacement therapy in people with neurodevelopmental disorders: A prospective cohort study
    Taha Itani
    Dheeraj Rai
    Tim Jones
    Gemma M. J. Taylor
    Kyla H. Thomas
    Richard M. Martin
    Marcus R. Munafò
    Neil M. Davies
    Amy E. Taylor
    [J]. Scientific Reports, 9
  • [7] Long-term effectiveness and safety of varenicline and nicotine replacement therapy in people with neurodevelopmental disorders: A prospective cohort study
    Itani, Taha
    Rai, Dheeraj
    Jones, Tim
    Taylor, Gemma M. J.
    Thomas, Kyla H.
    Martin, Richard M.
    Munafo, Marcus R.
    Davies, Neil M.
    Taylor, Amy E.
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [8] Varenicline versus nicotine replacement therapy for long-term smoking cessation: an observational study using the Clinical Practice Research Datalink
    Davies, Neil M.
    Taylor, Amy E.
    Taylor, Gemma M. J.
    Itani, Taha
    Jones, Tim
    Martin, Richard M.
    Munafo, Marcus R.
    Windmeijer, Frank
    Thomas, Kyla H.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2020, 24 (09) : 1 - +
  • [9] Is nicotine replacement therapy an effective long-term smoking cessation aid?
    不详
    [J]. FORMULARY, 2002, 37 (10) : 501 - 503
  • [10] Comparative Effectiveness of Varenicline and Nicotine Replacement Therapy for Smoking Cessation in Older and Younger Smokers: A Prospective Cohort in Taiwan
    Chang, Po-Yin
    Shiu, Ming-Neng
    Yuan, Yu-Ting
    Chang, Hui-Chin
    Su, Pei-Yu
    Lan, Tsuo-Hung
    [J]. NICOTINE & TOBACCO RESEARCH, 2019, 21 (02) : 149 - 155